Adalimumab treatment for pyoderma gangrenosum.
Heffernan
Michael P
MP
Divisions of Dermatology, Wright State University School of Medicine, Dayton, Ohio 45408, USA. michael.heffernan@wright.edu
Anadkat
Milan J
MJ
Smith
David I
DI
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab